2024/06/27 Matters Concerning Controlling Shareholders （184KB）
2024/06/27 Takara Bio announces the business partnership with Gap Junction Therapeutics to develop AAV gene therapy for hereditary hearing loss
2024/05/28 Notice of the 22nd Annual General Meeting of Shareholders （201KB）
2024/05/10 Notice Concerning Dividends from Surplus （139KB）
2024/05/10 Consolidated Financial Results for the Fiscal Year Ended March 31, 2024 (Under Japanese GAAP) （445KB）
2024/02/14 Consolidated finacial results for the nine months ended Dec 31(Under Japanese GAAP) （368KB）
2023/11/13 Takara Bio Announces "SonuAAV™", a Novel AAV Vector for Efficient Gene Transfer to the Inner Ear Organ.
2023/11/09 Notice Concerning Differences between the Financial Results Forecasts and the Actual Results （163KB）
2023/11/09 Notice Concerning Revisions to the Financial Results Forecasts （177KB）
2023/11/09 Consolidated Financial Results for the Six Months Ended September 30, 2023 (Under Japanese GAAP) （427KB）
2023/10/12 Construction of the Center for Cell and Gene Processing III, which manufactures mRNA vaccine ingredients and enzymes for mRNA production
2023/10/05 Takara Bio Announces Publication of Results from NY-ESO-1・siTCR™ Gene Therapy Study in Clinical Cancer Research
2023/10/03 Takara Bio Announces Presentation of Comparability Studies forCD19 JAK/STAT CAR-T Cell Technology Transfer
2023/09/25 Takara Bio enters into a license agreement of RetroNectin®with Fondazione Telethon ETS
2023/08/30 {Delayed] Corporate Governance Report （1,523KB）
2023/08/08 Consolidated Financial Results for the Three Months Ended June 30, 2023 (Under Japanese GAAP) （424KB）
2023/08/08 Notice Concerning Revisions to the First Half Financial Results Forecasts （179KB）
2023/08/01 Started using refrigerated boxes for transportation with consideration for the environment
2023/07/31 [Delayed] Annual Securities Report for Fiscal Year Ended March 31, 2023 （1,551KB）
2023/06/29 Matters Concerning Controlling Shareholders （241KB）
2023/05/29 Takara Bio Announces Poster Presentation of Data from Clinical Trial of NY-ESO-1・siTCR™ Gene Therapy at ASCO2023
2023/05/11 Notice Concerning Dividends from Surplus （232KB）
2023/05/11 Takara Bio Group Formulated “Medium-Term Management Plan 2026” （350KB）
2023/05/11 Consolidated Financial Results for the Fiscal Year Ended March 31, 2023 (Under Japanese GAAP) （610KB）
2023/04/19 Indian subsidiary acquires ISO13485 certification
2023/04/03 Takara Bio Announces Initiation of Clinical Trial for Next-Generation CAR-T therapy
2023/03/02 ARTICLES OF INCORPORATION （111KB）
2023/02/09 Notice Concerning Revisions to the Financial Results Forecasts and Dividend Forecasts （Dividend Increase） （252KB）
2023/02/09 Consolidated Financial Results for the Nine Months Ended December 31, 2022（Under Japanese GAA） （456KB）
2023/01/25 [Delayed]Takara Bio Announces Transfer of SAKIGAKE and Orphan Designations for NY-ESO-1/siTCR Gene Therapy Product （229KB）
2022/11/10 Announcement of Termination of Co-Development and Exclusive Marketing Agreements with Otsuka Pharmaceutical Co., Ltd. for NY-ESO-1・siTCR™ gene therapy candidate
2022/11/10 Notice Concerning Revisions to the Financial Results Forecasts and Dividend Forecasts (Dividend Increase) （186KB）
2022/11/10 Consolidated Financial Results for the Six Months Ended September 30, 2022 (Under Japanese GAAP) （404KB）
2022/10/25 Notice Concerning Revisions to the First Half Financial Results Forecasts （244KB）
2022/09/16 [Correction] Annual Securities Report for the Fiscal Year Ended March 31, 2022 （212KB）
2022/09/08 Launched CDMO service for gene therapy products using siTCR® technology or JAK/STAT technology
2022/09/06 Annual Report 2022 （8,041KB）
2022/08/29 [Delayed] Annual Securities Report for Fiscal Year Ended March 31, 2022 （1,191KB）
2022/08/04 Consolidated Financial Results for the Three Months Ended June 30, 2022 (Under Japanese GAAP) （394KB）
2022/07/22 Launched a CDMO service using CereAAV™, a brain-tropic AAV vector for gene therapy
2022/07/06 [Delayed] Corporate Governance Report （770KB）
2022/06/13 Notice of the 20th Annual General Meeting of Shareholders （208KB）
2022/06/01 Takara Bio to Present Clinical Data from Investigator-Initiated Trial in Canada of NY-ESO-1・siTCR™ Gene Therapy at ASCO2022【Poster Posted】
2022/05/12 Notice of Dividends of Surplus （135KB）
2022/05/12 Consolidated Financial Statements for the Year Ended March 31, 2022 FY2022 (April 1, 2021 - March 31, 2022) [UNAUDITED] （350KB）
2022/04/25 Takara Bio Announces a Novel Brain-Tropic AAV Vector "CereAAV™" for Gene Therapy
2022/02/10 Notice Concerning Forecast Revisions of Financial Results and Dividend (Dividend Increase) （250KB）
2022/02/10 Consolidated Financial Statements for the Third Quarter Ended December 31, 2021 FY2022 (April 1, 2021-March 31, 2022) [UNAUDITED] （771KB）
2022/01/24 Notice Concerning Recording of Extraordinary Gains and Losses Related to Subsidization （248KB）
2022/01/20 [Delayed] Corporate Governance Report （768KB）
2021/12/02 Implementation of the Center for Gene and Cell Processing to Respond to Diverse Modalities and Develop Supply Chains
2021/11/09 Announcement of Termination of Co-Development and Exclusive Marketing Agreements with Otsuka Pharmaceutical Co., Ltd. for Oncolytic virus HF10 and CD19-targeted CAR Gene Therapies
2021/11/09 Notice of Revisions of Financial Forecast and Dividend Forecast (Dividend Increase) （138KB）
2021/11/09 Consolidated Financial Statements for the Second Quarter Ended September 30, 2021 FY2022 (April 1, 2021 - March 31, 2022) [UNAUDITED] （339KB）
2021/10/21 Notice of Revision of Financial Forecast （241KB）
2021/09/21 Notice of Resolution of the Board of Directors on Selection of “Prime Market” Listing on the Tokyo Stock Exchange under the New Market Segments （224KB）
2021/08/06 [Updated] Consolidated Financial Statements for the First Quarter Ended June 30, 2021 FY2022 (April 1, 2021 - June 30, 2021) [UNAUDITED] （596KB）
2021/08/06 [Updated] Consolidated Financial Statements for the First Quarter Ended June 30, 2021 FY2022 (April 1, 2021 - June 30, 2021) [UNAUDITED] （154KB）
2021/08/03 Notice of Revision of Financial Forecast and Dividend Forecast (Dividend Increase) （139KB）
2021/08/03 Consolidated Financial Statements for the First Quarter Ended June 30, 2021 FY2022 (April 1, 2021 － June 30, 2021) 〔UNAUDITED〕 （596KB）
2021/05/13 Consolidated Financial Statements for the Year Ended March 31, 2021 FY2021 (April 1, 2020 - March 31, 2021) [UNAUDITED] （695KB）
2021/02/10 Notice Regarding Forecast Revisions of Financial Results and Dividend (Dividend Increase) （287KB）
2021/02/10 Consolidated Financial Statements for the Third Quarter Ended December 31, 2020 FY2021 (April 1, 2020 - March 31, 2021)［UNAUDITED］ （915KB）
2021/02/01 Takara Bio Acquires ISO13485 Certification
2021/01/05 Corporate Governance Report （681KB）
2020/11/25 We have posted "Financial Results Presentation". （1,020KB）
2020/11/10 Notice Regarding Forecast Revisions of Financial Results and Dividend (Dividend Increase) （217KB）
2020/11/10 Consolidated Financial Statements for the Second Quarter Ended September 30, 2020 FY2021 (April 1, 2020 - September 30, 2020) [UNAUDITED] （681KB）
2020/11/06 We have issued "Annual Report 2020". （1,023KB）
2020/10/21 【Delayed】Announcement on Revision of Financial Forecast （225KB）
2020/08/05 【Delayed】Announcement on revision of financial forecast （369KB）
2020/08/05 【Delayed】Consolidated Financial Statements for the First Quarter Ended June 30, 2020 FY2021 (April 1, 2020 - June 30, 2020) （780KB）
2020/08/04 Summary of Financial Results for the first quarter 2021 （366KB）
2020/08/04 Takara Bio terminates the license agreement relating to Oncolytic Virus C-REV with Tasly Biopharmaceuticals, China （285KB）
2020/06/26 We have posted "Financial Results Presentation". （670KB）
2020/06/24 Clinical program for NY-ESO-1・siTCR(TM) gene therapy candidate receives designation in Japan as Orphan Regenerative Medicine
2020/06/08 Takara Bio Group’s Formulation of Long-Term Management Plan FY2026 and Medium-Term Management Plan FY2023 （994KB）
2020/05/28 Notice of the 18th Annual General Meeting of Shareholders （163KB）
2020/05/19 【Delayed】Consolidated Financial Statements for the Year Ended March 31, 2020 FY2020 (April 1, 2019 -March 31, 2020)[UNAUDITED] （710KB）
2020/05/14 Summary of Financial Results 2020 （430KB）
2020/05/13 【Delayed】Takara Bio has entered into a license agreement relating to C-REV with Tasly Biopharmaceuticals, China （227KB）
2020/03/06 Takara Bio to Support Development of Novel Coronavirus VaccineUndertaken by Osaka University Group
2020/02/13 Consolidated Financial Statements for the Third Quarter Ended December 31, 2019 FY2020 (April 1, 2019 - March 31, 2020)[UNAUDITED] （625KB）
2020/01/21 Takara Bio Launches a New Facility for the Research and Manufacturing of Regenerative Medicine Products
2020/01/16 Takara Bio and Tmunity Enter into License Agreement to Advance siRNA Technology to Improve T cell Therapies
2019/11/21 We have posted "financial results presentation". （551KB）
2019/11/12 Consolidated Financial Statements for the Second Quarter Ended September 30, 2019 FY2020 (April 1, 2019 - March 31, 2020)[UNAUDITED] （626KB）
2019/09/27 Strategic Change in Development of Oncolytic Virus Immunotherapy C-REV （247KB）
2019/09/27 We have issued "Annual Report 2019". （1,044KB）
2019/09/24 Takara Bio to Present Clinical Data of Oncolytic Virus C-REV and NY-ESO-1・siTCR Gene Therapy at ESMO 2019
2019/08/14 Corporate Governance Report （514KB）
2019/08/06 Consolidated Financial Statements for the First Quarter Ended June 30, 2019 FY2020 (April 1, 2019 - March 31, 2020)[UNAUDITED] （583KB）
2019/05/30 Notice of the 17th Annual General Meeting of Shareholders （148KB）
2019/05/22 We have posted "Financial Results Presentation". （820KB）
2019/05/16 Takara Bio to Present Clinical Data of Oncolytic Virus C-REV and NY-ESO-1・siTCR Gene Therapy at ASCO 2019
2019/05/14 Consolidated Financial Statements for the Year Ended March 31, 2019 FY2019 (April 1, 2018 - March 31, 2019)［UNAUDITED］ （795KB）
2019/05/14 Summary of Financial Results 2019 （399KB）
2019/05/07 A wholly-owned subsidiary, Takara Biotechnology (Dalian) Co., Ltd.Acquires ISO:13485 certification
2019/04/26 Takara Bio to Acquire an Exclusive License to Use Patent Technology Relating to New Generation CAR Gene Therapy
2019/04/26 Joint Research on New Development of CAR Gene Therapy with Mie University
2019/04/24 Joint Research on Novel Approach to Cancer Immune and Gene Therapy with Department of Immunotherapeutics, The University of Tokyo Hospital
2019/04/03 Takara Bio Submits Drug Master File to the U.S. FDA for RetroNectin® GMP grade (Solution Type)
2019/03/29 Marketing Authorization Application for Oncolytic Virus Immunotherapy C-REV for Unresectable or Metastatic Melanoma Submitted in Japan （194KB）
2019/02/15 Designation Description Change of NY-ESO-1・siTCR gene therapy product under “SAKIGAKE Designation System”
2019/02/08 Corporate Governance Report （496KB）
2019/02/06 【Delayed】Consolidated Financial Statements for the Third Quarter Ended December 31, 2018 FY2019 (April 1, 2018 - March 31, 2019)[UNAUDITED] （932KB）
2019/01/30 Notice Regarding Forecast Revisions of Financial Results and Dividend (Dividend Increase) （259KB）
2019/01/30 Summary of Financial Results for the third quarter 2019 （488KB）
2019/01/16 Takara to Present Oncolytic Virus C-REV Preliminary Data from the Phase I trial Targeting Unresectable Pancreatic Cancer at ASCO-GI 2019 Congress
2018/12/17 Notice Regarding Transfer of Mushroom Business （316KB）
2018/11/14 We have posted "Financial Results Presentation". （684KB）
2018/11/06 Consolidated Financial Statements for the Second Quarter Ended September 30, 2018 FY2019 (April 1, 2018 - March 31, 2019)[UNAUDITED] （728KB）
2018/11/06 Summary of Financial Results for the second quarter 2019 （390KB）
2018/10/22 Announcement of Participation in AMED Project “Research and development of core technologies for gene and cell therapy”
2018/10/19 Oncolytic Virus C-REV Data Presentation of Phase II trial Targeting Unresectable or Metastatic Melanoma in Japan at ESMO 2018 Congress
2018/10/15 CAP-LAP Certification of Clinical Testing Laboratory for Takara Bio's Cancer Genetic Testing Business conducted in Osaka University Hospital
2018/09/28 【Delayed】Notice Regarding Business Reorganization by Simplified Absorption-type Company Split （241KB）
2018/09/03 Out-licensing agreement for commercial use of RetroNectin® into Daiichi Sankyo
2018/09/03 We have issued "Annual Report 2018". （2,549KB）
2018/08/22 Takara Bio entered into a licensing agreement relating to Oncolytic Virus "Canerpaturev" with Dong-A ST, South Korea （195KB）
2018/07/31 Consolidated Financial Statements for the First Quarter Ended June 30, 2018 FY2019(April 1, 2018-March 31, 2019)[UNAUDITED] （182KB）
2018/07/31 Summary of Financial Results for the first quarter 2019 （109KB）
2018/07/26 Takara Bio granted manufacturing license from the Swedish Medical Product Agency for clinical-grade human embryonic stem cell line derivation and banking
2018/06/08 【Delayed】Announcement on revision of Takara Bio Medium-Term Management Plan FY2020 （533KB）
2018/06/08 【Delayed】Consolidated Financial Statements for the Year Ended March 31, 2018 FY2018 (April 1, 2017 - March 31, 2018)[UNAUDITED] （780KB）
2018/05/31 Takara Bio presents HF10 Phase II clinical trial data at American Society of Clinical Oncology
2018/04/09 Takara Bio entered into an agreement for co-development/exclusive sales of NY-ESO-1・siTCR and CD19 CAR gene therapy with Otsuka
2018/04/06 Announcement on product designation of NY-ESO-1・siTCR gene therapy product for synoviral sarcoma under “SAKIGAKE Designation System” by the Ministry of Health, Labour and Welfare
2018/02/19 Takara Bio to Establish a New Facility for the Research and Manufacturing of Regenerative Medical Products
2018/02/13 【Delayed】Consolidated Financial Statements for the Third Quarter Ended December 31, 2017 FY2017 (April 1, 2017 - March 31, 2018) [UNAUDITED] （832KB）
2018/01/30 Summary of Financial Results for the third quarter 2018 （96KB）
2018/01/19 First patient enrolled into phase I/II clinical trial of NY-ESO-1・siTCR gene therapy against synovial sarcoma in Japan
2017/12/21 Announcement on investigator-initiated clinical trial of neoadjuvant combination therapy with HF10 and Nivolumab
2017/11/28 Consolidated Financial Statements for the Second Quarter Ended September 30, 2017 （1,571KB）
2017/11/06 Revision of Consolidated Business Results Forecast ｆor the First Half of the Fiscal Year Ending March 31, 2018 （221KB）
2017/11/06 Exclusive Global License for New Method of iPS Cell Production Obtained
2017/09/27 First patient enrolled into phase I clinical trial of Oncolytic Virus HF10 against pancreatic cancer in Japan
2017/08/21 Consolidated Financial Statement for the First Quarter Ended June 30, 2017 （891KB）
2017/07/27 Summary of Consolidated Financial Statement for the First Quarter Ended June 30, 2017 （367KB）
2017/06/01 Announcement on submission of the Clinical Trial Plan Notification for phase I clinical trial of Oncolytic virus HF10 against pancreatic cancer in Japan
2017/05/29 First patient enrolled into Oncolytic Virus HF10 phase II clinical trial in Japan
2017/05/23 Takara Bio presents HF10 Phase II clinical trial data at American Society of Clinical Oncology
2017/05/09 Consolidated Financial Statement for the year ended March 31, 2017, released on May 9, 2017 （791KB）
2017/05/09 Formulation of Takara Bio Medium-Term Management Plan FY2020 （243KB）
2017/03/01 Takara Bio USA Holdings, Inc. completes acquisition of WaferGen Bio-systems, Inc.
2017/01/30 Announcement on submission of the Clinical Trial Plan Notification for phase II clinical trial of Oncolytic virus HF10 in Japan
2017/01/24 Announcement on submission of the Clinical Trial Plan Notification for phase I/II clinical trial of NY-ESO-1・siTCR gene therapy in Japan
2017/01/18 Takara Bio USA Holdings, Inc. completes acquisition of Rubicon Genomics, Inc.
2017/01/11 Announcement on submission of the Clinical Trial Plan Notification for phase I/II clinical trial of CAR gene therapy in Japan
2016/12/15 Takara Bio Signs Exclusive License Agreement with Otsuka for the Investigational Cancer Treatment HF10, an Oncolytic Virus
2016/12/15 Takara Bio USA Holdings, Inc. and Rubicon Genomics Announce Merger Agreement
2016/06/21 Takara Bio enters into a license and supply agreement of RetroNectin® with Kite Pharma
2016/05/19 Takara Bio presents HF10 Phase II clinical trial data at American Society of Clinical Oncology
2016/03/22 Takara Bio grants Cellectis SA a commercial license to use RetroNectin®
2016/02/02 Center for Gene and Cell Processing wins 2016 Facility of the Year Awards
2016/01/27 Establishment of a cell processing facility in “Life Innovation Center (provisional name)” in Tono-machi, Kawasaki city, as the implementation/ industrialization hub for cell therapy and regenerative medicine
2016/01/25 Release of GMP grade PCR enzyme for genetic diagnosis
2016/01/14 Notice of change in the Company Name, consolidated subsidiary, United States-based Clontech Laboratories, Inc.
2015/10/27 HF10 Phase II clinical trial data presented at AACR-NCI-EORTC international conference
2015/09/29 Licensing agreement for manufacturing iPS cells using Sendai virus vector
2015/09/14 HF10 Phase I clinical trial data presented at European Society for Medical Oncology 2015 Congress
2015/08/10 Completion of a new facility and relocation of head office
2015/08/04 The 1st HF10 therapy in Japan was started against solid cancers
2015/07/24 Regenerative medicine based on dental pulp cells
2015/07/23 Takara Bio launches High-performance real-time PCR system
2015/06/17 Acquisition of ISO 9001 certification aiming at improvement in quality of products and services in regenerative medicine fields
2015/06/10 Patent regarding siTCR vector a core technique of gene therapy is granted in the U.S.
2015/06/01 Takara Bio launches culture medium specifically designed for iPS cells for research-use in regenerative medicine field
2015/05/19 Takara Bio is selected for ”Project Focused on Developing Key Evaluation Technology: Evaluation for Industrialization in the Field of Regenerative Medicine”
2015/05/13 Accreditation of the foreign cell processor: Takara Bio can start specific processed cell manufacturing and provide contracted cell processing service to medical institutions
2014/11/10 Acquisition of assets for stem cell-related research products from StemCells Inc.
2014/11/04 License Agreement with iPS Academia Japan Inc.
2014/10/30 Takara Bio receives NEDO Grant to develop mass production of cardiomyocytes derived from human iPS cells
2014/10/27 License agreement for genome editing with Broad Institute
2014/10/01 Marketing of Cellartis™ products started
2014/07/29 Acquisition of stem cell business firm (former Cellartis AB) from Cellectis SA
2014/06/24 Agreement with iHeart Japan Corporation
2014/05/30 Takara Bio reseives NEDO Grant to develop cell manufacturing and processing systems for industrialization of regenerative medicine
2014/05/08 Takara Bio Group’s Mid-term Management Plan
2014/05/01 Takara Bio submitted an Investigational New Drug application for a Phase II clinical trial of HF10 anti-cancer therapy to the Food and Drug Administration
2014/03/13 Clinical research protocol of gene therapy targeting B cell non-Hodgkin Lymphoma was approved by Japanese Ministry
2014/03/03 Takara Bio obtains a governmental grant for commercialization of its TCR gene therapy projects
2014/02/10 Submission of the application for Investigator-initiated Phase I clinical trials of MAGE-A4 TCR gene therapy as Japan’s first genetic immunotherapy for cancer
2014/01/09 Takara Bio releases Mouse Feeder Cell Quantification Kit for quality control of human stem cells
